If you’ve got a patent-protected drug that’s bringing in more than $1 billion a year in sales, you stand to lose a significant chunk of that revenue when the patent expires and lower-cost generic versions come on the market. A California prosecutor alleges that a number of drug companies illegally colluded in a nearly decade-long “pay-for-delay” deal intended to prevent the release of a cheaper competitor to a popular cholesterol drug. [More]
In recent weeks, members of both the House and Senate have raised questions about the soaring price of — and potential antitrust concerns surrounding — emergency allergy treatment EpiPen. A congressional committee confirmed this morning that it will soon hold a hearing on the issue, and that Heather Bresch, CEO of EpiPen maker Mylan, has been called to testify. [More]
Teva sandals are no longer for granola-crunching outdoors types. Now the fashion-conscious adventurer can go straight from the rugged rocks to the black-tie fundraiser without missing a beat.
Generic prescription drugs are just that: generic. Most patients don’t think much about who actually manufactures them. It’s pretty likely, however, that you have something in your medicine cabinet manufactured by Israel’s Teva Pharmaceutical Industries Ltd. A profile of the company in this past weekend’s New York Times is fascinating. Most interesting of all: while the company is sensibly frugal enough to make Captain Moneycat purr, they refuse to move manufacturing to China or India, as many of their competitors have.